WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Biofortuna Ltd
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Sutro Biopharma | June 22, 2020
Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced the presentation of new preclinical data for its folate receptor alpha (FolRα) targeting antibody-drug conjugate, STRO-002, at the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II from June 22-24, 2020. The data,...
Industrial Impact, Medical
Kymanox | February 06, 2023
Kymanox, a leading life science-focused professional services firm, recently announced the acquisition of anteris medical GmbH and anteris helvetia AG (collectively anteris). Anteris specializes in assisting the commercialization and development of medical equipment, combination and in-vitro diagnostic products. This acquisition enables both firms to achieve their common organizational goal of geographic expansion while enhancing their service capabilities by offering clients a ...
QS WOWNEWS | July 18, 2020
Researchers of Peter the Great St. Petersburg Polytechnic University (SPbPU) in collaboration with Hamburg University of Technology (TUHH) completed an international joint project to create a resource and CO2-neutral energy closed-loop technology from microalgae Chlorella sorokiniana and duckweed Lemna minor.According to Professor Kerstin Kuchta, Vice president of TUHH and the project coordinator from the German side, the main objective of the project was development and implementati...
BioSpace | March 04, 2020
Amunix Pharmaceuticals Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent immune-activating biotherapeutics to patients with solid tumor cancers, today announced the successful completion of an oversubscribed $73 million Series A financing. Boston-based Omega Funds led the financing, with participation from existing investor Frazier Healthcare Partners and new investors Longitude Capital, Redmile Group, Polaris Partners, C...
Industry Outlook
Whitepaper
Research, Medical
Cell and Gene Therapy, Medical
Cell and Gene Therapy
Video
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE